Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019'; Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes.
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.
The report 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019' outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 6, 4 and 14 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Respiratory, Gastrointestinal, Hematological Disorders, Infectious Disease, Oncology, Central Nervous System, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Immunology and Musculoskeletal Disorders which include indications Glaucoma, Ocular Hypertension, Pulmonary Arterial Hypertension, Diabetic Nephropathy, Diastolic Heart Failure, Open-Angle Glaucoma, Sickle Cell Disease, Acute Heart Failure, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Chronic Kidney Disease (Chronic Renal Failure), Chronic Thromboembolic Pulmonary Hypertension, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Cystic Fibrosis, Diabetic Foot Ulcers, Duchenne Muscular Dystrophy, Inflammation, Ischemic Stroke, Liver Diseases, Liver Fibrosis, Lung Disease, Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Onychomycosis (Tinea Unguium), Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Hypertension, Stroke, Systolic Heart Failure, Tinea Pedis (Athlete Foot), Vascular Dementias, Vaso-Occlusive Crisis Associated With Sickle Cell Disease and Wounds.
SCOPE
SUMMARY
According to the recently published report 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019'; Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes.
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.
The report 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019' outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 6, 4 and 14 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Respiratory, Gastrointestinal, Hematological Disorders, Infectious Disease, Oncology, Central Nervous System, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Immunology and Musculoskeletal Disorders which include indications Glaucoma, Ocular Hypertension, Pulmonary Arterial Hypertension, Diabetic Nephropathy, Diastolic Heart Failure, Open-Angle Glaucoma, Sickle Cell Disease, Acute Heart Failure, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Chronic Kidney Disease (Chronic Renal Failure), Chronic Thromboembolic Pulmonary Hypertension, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Cystic Fibrosis, Diabetic Foot Ulcers, Duchenne Muscular Dystrophy, Inflammation, Ischemic Stroke, Liver Diseases, Liver Fibrosis, Lung Disease, Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Onychomycosis (Tinea Unguium), Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Hypertension, Stroke, Systolic Heart Failure, Tinea Pedis (Athlete Foot), Vascular Dementias, Vaso-Occlusive Crisis Associated With Sickle Cell Disease and Wounds.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
AntiRadical Therapeutics LLC
Bayer AG
Boehringer Ingelheim International GmbH
Cyclerion Therapeutics Inc
Ebelle Pharmaceuticals Inc
NicOx SA
Novan Inc
Novartis AG
Novoteris LLC
Toa Eiyo Ltd
Topadur Pharma AG
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
A-8R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1237592 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-546544 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-703704 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxyurea - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
AntiRadical Therapeutics LLC
Bayer AG
Boehringer Ingelheim International GmbH
Cyclerion Therapeutics Inc
Ebelle Pharmaceuticals Inc
NicOx SA
Novan Inc
Novartis AG
Novoteris LLC
Toa Eiyo Ltd
Topadur Pharma AG
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
A-8R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1237592 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-546544 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-703704 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxyurea - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AntiRadical Therapeutics LLC, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Cyclerion Therapeutics Inc, H2 2019
Pipeline by Ebelle Pharmaceuticals Inc, H2 2019
Pipeline by NicOx SA, H2 2019
Pipeline by Novan Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Novoteris LLC, H2 2019
Pipeline by Toa Eiyo Ltd, H2 2019
Pipeline by Topadur Pharma AG, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AntiRadical Therapeutics LLC, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Cyclerion Therapeutics Inc, H2 2019
Pipeline by Ebelle Pharmaceuticals Inc, H2 2019
Pipeline by NicOx SA, H2 2019
Pipeline by Novan Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Novoteris LLC, H2 2019
Pipeline by Toa Eiyo Ltd, H2 2019
Pipeline by Topadur Pharma AG, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AntiRadical Therapeutics LLC
Bayer AG
Boehringer Ingelheim International GmbH
Cyclerion Therapeutics Inc
Ebelle Pharmaceuticals Inc
NicOx SA
Novan Inc
Novartis AG
Novoteris LLC
Toa Eiyo Ltd
Topadur Pharma AG
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AntiRadical Therapeutics LLC
Bayer AG
Boehringer Ingelheim International GmbH
Cyclerion Therapeutics Inc
Ebelle Pharmaceuticals Inc
NicOx SA
Novan Inc
Novartis AG
Novoteris LLC
Toa Eiyo Ltd
Topadur Pharma AG
